- Home
- AIRS vs NKTR Comparison
AIRS vs NKTR Comparison
Compare AIRS & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- NKTR
- Stock Information
- Founded
- AIRS 2012
- NKTR 1990
- Country
- AIRS United States
- NKTR United States
- Employees
- AIRS N/A
- NKTR N/A
- Industry
- AIRS Medical/Nursing Services
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- NKTR Health Care
- Exchange
- AIRS Nasdaq
- NKTR Nasdaq
- Market Cap
- AIRS 302.9M
- NKTR 238.7M
- IPO Year
- AIRS 2021
- NKTR 1994
- Fundamental
- Price
- AIRS $5.68
- NKTR $1.32
- Analyst Decision
- AIRS Hold
- NKTR Buy
- Analyst Count
- AIRS 2
- NKTR 4
- Target Price
- AIRS $5.50
- NKTR $2.50
- AVG Volume (30 Days)
- AIRS 135.0K
- NKTR 1.1M
- Earning Date
- AIRS 11-07-2024
- NKTR 11-05-2024
- Dividend Yield
- AIRS N/A
- NKTR N/A
- EPS Growth
- AIRS N/A
- NKTR N/A
- EPS
- AIRS N/A
- NKTR N/A
- Revenue
- AIRS $193,025,000.00
- NKTR $93,157,000.00
- Revenue This Year
- AIRS N/A
- NKTR N/A
- Revenue Next Year
- AIRS $11.85
- NKTR N/A
- P/E Ratio
- AIRS N/A
- NKTR N/A
- Revenue Growth
- AIRS 6.58
- NKTR 6.17
- 52 Week Low
- AIRS $2.92
- NKTR $0.41
- 52 Week High
- AIRS $8.30
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- AIRS 64.02
- NKTR 54.62
- Support Level
- AIRS $4.62
- NKTR $1.24
- Resistance Level
- AIRS $5.40
- NKTR $1.42
- Average True Range (ATR)
- AIRS 0.47
- NKTR 0.09
- MACD
- AIRS 0.03
- NKTR 0.01
- Stochastic Oscillator
- AIRS 73.74
- NKTR 67.74
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.